NFKB1 and diffuse large B-cell lymphoma: In addition, the activation of nuclear factor κB (NF-κB) occurs in most non-germinal center B-cell (non-GCB)-derived DLBCL cases [10], and the first NF-κB pathway inhibitors are currently being tested in clinical studies [11].